Literature DB >> 31107721

Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer.

Shiho Asaka1, Christine Davis2, Shiou-Fu Lin2, Tian-Li Wang1,2,3, Christopher M Heaphy1,2, Ie-Ming Shih1,2,3.   

Abstract

Telomere alterations represent one of the major molecular changes in the development of human cancer. We have previously reported that telomere lengths in most serous tubal intraepithelial carcinomas (STIC) are shorter than they are in ovarian high-grade serous carcinomas (HGSC) or in normal-appearing fallopian tube epithelium from the same patients. However, it remains critical to determine if similar telomere alterations occur in TP53-mutated but histologically unremarkable "p53 signature" lesions, as well as incidental STICs without concurrent HGSC. In this study, we quantitatively measured telomere lengths by performing telomere-specific fluorescence in situ hybridization in conjunction with p53 immunolabeling in 15 p53 signatures and 30 incidental STICs without concurrent HGSC. We compared these new results with our previous data in paired STICs and concurrent HGSCs. We found that most p53 signatures (80%) and incidental STICs without HGSC (77%) exhibited significant telomere shortening compared with adjacent normal-appearing fallopian tube epithelium (P<0.01). Interestingly, however, p53 signatures and incidental STICs without HGSC displayed longer telomeres and less cell-to-cell telomere length heterogeneity than STICs associated with HGSC (P<0.001). These findings indicate that telomere shortening occurs in p53 signatures, the earliest precancer lesion. Moreover, incidental STICs without concurrent HGSC are indeed similar to p53 signatures as they have less telomere shortening and less cell-to-cell telomere length heterogeneity than STICs associated with HGSC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31107721      PMCID: PMC6629487          DOI: 10.1097/PAS.0000000000001283

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  46 in total

1.  Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining.

Authors:  Alan K Meeker; Wesley R Gage; Jessica L Hicks; Inpakala Simon; Jonathan R Coffman; Elizabeth A Platz; Gerrun E March; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

2.  p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis.

Authors:  L Chin; S E Artandi; Q Shen; A Tam; S L Lee; G J Gottlieb; C W Greider; R A DePinho
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

3.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

4.  Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.

Authors:  T Kanaya; S Kyo; K Hamada; M Takakura; Y Kitagawa; H Harada; M Inoue
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

Review 5.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

6.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis.

Authors:  Alan K Meeker; Jessica L Hicks; Elizabeth A Platz; Gerrun E March; Christina J Bennett; Michael J Delannoy; Angelo M De Marzo
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

7.  Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.

Authors:  D Xu; Q Wang; A Gruber; M Björkholm; Z Chen; A Zaid; G Selivanova; C Peterson; K G Wiman; P Pisa
Journal:  Oncogene       Date:  2000-10-26       Impact factor: 9.867

8.  Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma.

Authors:  Donna E Hansel; Alan K Meeker; Jessica Hicks; Angelo M De Marzo; Keith D Lillemoe; Richard Schulick; Ralph H Hruban; Anirban Maitra; Pedram Argani
Journal:  Mod Pathol       Date:  2006-06       Impact factor: 7.842

9.  Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis.

Authors:  Alan K Meeker; Jessica L Hicks; Christine A Iacobuzio-Donahue; Elizabeth A Montgomery; William H Westra; Theresa Y Chan; Brigitte M Ronnett; Angelo M De Marzo
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

10.  Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma.

Authors:  Alan K Meeker; Jessica L Hicks; Edward Gabrielson; William M Strauss; Angelo M De Marzo; Pedram Argani
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more
  5 in total

1.  Pathologic Classification of Ovarian Cancer.

Authors:  Stephanie M McGregor
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

3.  Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.

Authors:  Tomas Goncalves; Georgia Zoumpoulidou; Carlos Alvarez-Mendoza; Caterina Mancusi; Laura C Collopy; Sandra J Strauss; Sibylle Mittnacht; Kazunori Tomita
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-07

4.  The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy.

Authors:  Christopher M Heaphy; Corinne E Joshu; Elizabeth A Platz; Alan K Meeker; John R Barber; Christine Davis; Jiayun Lu; Reza Zarinshenas; Edward Giovannucci; Lorelei A Mucci; Meir J Stampfer; Misop Han; Angelo M De Marzo; Tamara L Lotan
Journal:  J Pathol Clin Res       Date:  2022-07-14

5.  Methylomic Landscapes of Ovarian Cancer Precursor Lesions.

Authors:  Thomas R Pisanic; Yeh Wang; Hanru Sun; Michael Considine; Lihong Li; Tza-Huei Wang; Tian-Li Wang; Ie-Ming Shih
Journal:  Clin Cancer Res       Date:  2020-08-17       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.